2009
DOI: 10.1517/14656560902775750
|View full text |Cite
|
Sign up to set email alerts
|

Bupropion and naltrexone: a review of their use individually and in combination for the treatment of obesity

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

1
25
0
1

Year Published

2009
2009
2021
2021

Publication Types

Select...
7
3

Relationship

0
10

Authors

Journals

citations
Cited by 45 publications
(27 citation statements)
references
References 24 publications
1
25
0
1
Order By: Relevance
“…Bupropion has numerous therapeutic indications including, depression [3], smoking cessation [4], sexual dysfunction [5], obesity [6], attention deficit hyperactivity disorder [7] and seasonal affective disorder [8]. It has recently been shown to have anti-inflammatory properties [9].…”
Section: Introductionmentioning
confidence: 99%
“…Bupropion has numerous therapeutic indications including, depression [3], smoking cessation [4], sexual dysfunction [5], obesity [6], attention deficit hyperactivity disorder [7] and seasonal affective disorder [8]. It has recently been shown to have anti-inflammatory properties [9].…”
Section: Introductionmentioning
confidence: 99%
“…Contrave is an experimental treatment for obesity in phase III clinical trials and is a combination of naltrexone and buproprion [40]. Each component has demonstrable efficacy as a weight loss agent.…”
Section: Combination Formulationsmentioning
confidence: 99%
“…One combination receiving special attention is the addition of naltrexone to bupropion, and several trials are ongoing [30].…”
Section: Bupropionmentioning
confidence: 99%